Dan Rudmann is an experienced professional in the field of pathology, currently serving as the Executive Director of Pathology at Moderna. Prior roles include Senior Director, Interim Director, and Scientific Director (Product Owner) of Digital Pathology at Charles River Laboratories, as well as Vice President of Program Development at Flagship Biosciences, Inc. Dan also held the position of Global Head of Pathology at AstraZeneca and was the Head (Director) of Pathology and Program Team Leader in Early Phase Development at Eli Lilly and Company. Dan Rudmann's educational background includes a DVM and PhD from Purdue University and completion of the Enterprise Leadership Executive Course at the Massachusetts Institute of Technology.
June, 2024 - present